Semaglutide vs Tirzepatide: An Honest Comparison

If you’re weighing up GLP-1 treatment in 2026, the decision usually comes down to two molecules: semaglutide (sold as Wegovy for weight loss, Ozempic for diabetes) and tirzepatide (Zepbound for weight loss, Mounjaro for diabetes).

Ask the internet and you’ll get tribal answers. Ask the trial data and you get something more useful.

The short version

Tirzepatide produces more weight loss on average. Semaglutide has the stronger cardiovascular evidence and a longer safety track record. Both are effective, both have similar side effect profiles, and for many people the deciding factors end up being availability, price, and how their own body responds, not the trial averages.

Now the details.

Head to head: the SURMOUNT-5 trial

For years, the two drugs could only be compared across separate trials, which is statistically messy. That changed with SURMOUNT-5, a head-to-head randomized trial in adults with obesity and no diabetes:

That’s a real difference, not a rounding error. If maximum weight loss is the only criterion, tirzepatide wins on the evidence we have.

But “only criterion” is doing a lot of work in that sentence.

Where semaglutide pushes back

Cardiovascular outcomes. The SELECT trial showed semaglutide reduced major cardiovascular events (heart attack, stroke, cardiovascular death) by about 20% in people with existing heart disease and overweight. That earned it a formal indication. Tirzepatide’s cardiovascular outcome data is still maturing; its trial program came later. If you have established heart disease, this evidence gap is a legitimate reason a cardiologist might prefer semaglutide today.

Track record. Semaglutide has been in wide use since 2017 (as Ozempic), giving it years of additional real-world safety data. Nothing alarming has surfaced with tirzepatide, but “we’ve watched it longer” is worth something in medicine.

An oral option exists in the family. Semaglutide is the only one of the two available as a daily pill (Rybelsus, for diabetes), and oral formulations for weight loss have been in development. If needles are a dealbreaker, the semaglutide family is where the options are.

What they share

More than the marketing suggests:

• Weekly injection, same style of auto-injector pen or vial-and-syringe options.
• The same escalation ritual. Both start at a low dose and step up every four weeks or so, largely to let your gut adapt.
• The same core side effects. Nausea early on, constipation, occasional vomiting, and the rarer serious risks (pancreatitis, gallbladder issues). Neither is clearly “gentler” in trials, though individuals often tolerate one better than the other, and there’s no way to predict which in advance.
• The same regain problem when stopped. Neither drug changes the underlying biology. Stop either one and appetite returns.

Cost and access

List prices for both sit above $1,000/month in the US, but almost nobody should pay list price anymore. Both manufacturers now sell direct to cash-pay patients at substantially lower prices through their own channels, and prices have been moving down through 2025 and 2026 as competition and political pressure squeezed the category. Insurance coverage remains a lottery that depends on your plan, not on which drug is “better.”

We keep a separate, regularly updated breakdown in our cost guide.

So which one?

Our honest read of the evidence:

• Chasing maximum weight loss, no heart disease: the data favors tirzepatide.
• Established cardiovascular disease: semaglutide has the outcome trial behind it. Have that conversation with your cardiologist.
• Tried one and struggled with side effects or a plateau: switching to the other is a recognized, reasonable move. Plenty of people tolerate one noticeably better.
• Deciding on price: compare the actual monthly cost you’d pay through insurance or direct programs. A drug you can afford for two years beats a slightly stronger one you abandon after four months. This is not a small point. Discontinuation is the biggest predictor of regain.

One thing we’d push back on: agonizing over this choice as if it’s permanent. It isn’t. Prescribers switch patients between these medications all the time based on response, tolerance, and coverage. The more important decisions are the ones that apply to both drugs: committing to protein and resistance training so the weight you lose is fat, not muscle, and going in with a realistic plan for long-term treatment.

This article is for general education, not medical advice. Medication decisions should be made with a licensed clinician who knows your history.